10-Q · May 14, 2026
PDS Biotechnology Corporation reported a net loss of $7.3 million for Q1 2026, improving from a loss of $8.5 million in Q1 2025, while revenues remained at $0. The company's operating expenses decreased significantly by…
Earnings analysis · 10-Q
PDSB earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
PDS Biotech reduced operating expenses and year-to-date operating cash burn, but Q2 net loss increased 3% year over year to $9.75 million and EPS was $(0.18). The balance sheet deteriorated sharply, with cash falling to…
Read full summary
PDS Biotech reduced operating expenses and year-to-date operating cash burn, but Q2 net loss increased 3% year over year to $9.75 million and EPS was $(0.18). The balance sheet deteriorated sharply, with cash falling to $5.6 million, negative equity of $3.6 million, and current liabilities exceeding current assets by $5.3 million. Management’s strategic refocus toward PDS0301 offers a potential clinical catalyst, but discontinuation of the PDS0101 Phase 3 trial, Nasdaq deficiency, debt obligations, and an explicit going-concern warning create substantial financing and execution risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.18
- Segment
- Single reportable segment: targeted immunotherapy development; Q2 2026 segment/net loss was $9,750,575 versus $9,434,208 in Q2 2025. Segment expenses were $6,496,734 versus $7,623,351.
What stood out
-
Lower operating costs, but net loss worsened
Q2 2026 EPS was $(0.18), compared with $(0.21) in Q2 2025. Net loss increased 3% to $9,750,575 from $9,434,208 despite a 15% reduction in operating expenses.
-
Operating expenses fell 15% year over year
Operating expenses declined to $6,496,734 from $7,623,351, with R&D down 22% to $3,265,586 and G&A down 5% to $3,231,148. Management attributed the R&D decline primarily to $1.0 million lower clinical-trial costs and $0.4 million lower manufacturing costs.
-
Year-to-date spending was substantially reduced
Six-month R&D expense decreased 33% to $6,722,618, while total operating expenses fell 22% to $13,017,821. Management cited $2.1 million lower clinical-trial costs and $1.2 million lower manufacturing and quality costs.
-
Operating cash burn improved
Net cash used in operating activities improved to $7,164,155 in the first six months from $18,133,379 in the prior-year period. The improvement included working-capital timing effects and noncash items, including $2,660,781 of loss on debt retirement.
-
Legacy convertible debt was retired
The company completed redemption of its senior secured convertible debentures on June 15, 2026, paying 103% of principal plus accrued interest and other amounts. Noncurrent debt declined from $11,733,350 at December 31, 2025 to $0 at June 30, 2026.
-
PDS0301 became the lead program
Management is prioritizing PDS0301 after reporting Phase 2 colorectal cancer data showing a 77.8% objective response rate, or 7 of 9 patients, at six months, versus 35% or 7 of 20 patients in a parallel study without PDS0301.
What to watch
-
Severe liquidity and going-concern risk
Cash and cash equivalents fell 79% to $5,596,254 at June 30, 2026 from $26,711,969 at December 31, 2025. The company reported a $233,706,135 accumulated deficit, negative stockholders’ equity of $3,579,739, and substantial doubt about continuing as a going concern for at least 12 months.
-
Pipeline narrowed after PDS0101 trial stop
The company discontinued the VERSATILE-003 Phase 3 trial in August 2026 and ceased further internal investment in PDS0101. Management now depends on strategic partnerships or externally funded opportunities for PDS0101, while the company has become substantially more dependent on PDS0301.
-
Nasdaq minimum-bid-price deficiency
A new Nasdaq risk was disclosed: on July 30, 2026, the company received a deficiency letter after its closing bid price remained below $1.00 for 30 consecutive trading days. It has 180 calendar days to regain compliance, and failure could result in delisting.
-
Debt terms could accelerate cash outflows
The April 2026 Promissory Note has $6,000,000 principal, bears 10% annual interest, and matures June 15, 2027. Failure to cure the Nasdaq bid-price deficiency within 75 calendar days can trigger a special amortization event requiring a $2,000,000 principal payment, plus premium and accrued interest.
-
Negative working capital intensified
Accounts payable increased 79% to $6,393,967 and accrued expenses increased 120% to $1,629,313 from December 31, 2025. Total current liabilities of $12,377,476 exceeded current assets of $7,045,193 by $5,332,283.
-
PDS0301 advancement will raise funding needs
The company expects R&D expenses to increase significantly as PDS0301 enters additional clinical development, while six-month net loss was already $17,099,631 and six-month operating cash use was $7,164,155. Additional equity or debt financing may dilute shareholders or impose restrictive covenants.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management expects no product revenue in the near future, continued operating losses, and significantly higher R&D expenses as PDS0301 advances into clinical trials. The company also states that substantial doubt exists about its ability to continue as a going concern for at least 12 months.
Earlier filings 4
10-K · April 28, 2026
PDS Biotech remains a pre-commercial, clinical‑stage oncology biotech with no reported product revenue and an experienced board/management team that highlights dealmaking and capital‑raising track records. Q4 results…
10-K · March 30, 2026
PDS Biotech is a clinical-stage immunotherapy company with clear platform progress (Phase 3 initiation for PDS0101 and expansion triggers for PDS01ADC) but no product revenues and continuing cash burn. The 2025 filing…
10-Q · November 13, 2025
PDS Biotech reported continued operating losses but showed a modest quarter-over-quarter improvement in EPS. Net loss per share was $(0.19) for the three months ended September 30, 2025, compared with $(0.29) a year…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.